NewAmsterdam Pharma Company Statistics
Want to see NAMS full AI Analyst Report?
NewAmsterdam Pharma Company (NAMS) Stock Statistics & Valuation Metrics
Total Valuation
NewAmsterdam Pharma Company has a market cap or net worth of $2.42B. The enterprise value is $2.39B.
- Market Cap
- $2.42B
- Enterprise Value
- $2.39B
Share Statistics
NewAmsterdam Pharma Company has 119,930,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 119,930,000
- Owned by Insiders
- 0.37%
- Owned by Institutions
- 42.60%
Financial Efficiency
NewAmsterdam Pharma Company’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -33.01%.
- Return on Equity (ROE)
- -0.30
- Return on Assets (ROA)
- -0.26
- Return on Invested Capital (ROIC)
- -33.01%
- Return on Capital Employed (ROCE)
- -0.33
- Revenue Per Employee
- 225.03K
- Profits Per Employee
- -2.04M
- Employee Count
- 100
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NewAmsterdam Pharma Company is -11.78. NewAmsterdam Pharma Company’s PEG ratio is -1.43.
- PE Ratio
- -11.78
- PS Ratio
- 93.13
- PB Ratio
- 3.96
- Price to FCF
- -16.01
- Price to Operating Cash Flow
- -16.62
- PEG Ratio
- -1.43
Income Statement
In the last 12 months, NewAmsterdam Pharma Company had revenue of 22.50M and earned -203.82M in profits. Earnings per share was -1.75.
- Revenue
- 22.50M
- Gross Profit
- 22.44M
- Operating Income
- -225.68M
- Pretax Income
- -203.82M
- Net Income
- -203.82M
- EBITDA
- -242.32M
- Earnings Per Share (EPS)
- -1.75
Cash Flow
In the last 12 months, operating cash flow was -150.47M and capital expenditures -395,000, giving a free cash flow of -150.86M billion.
- Operating Cash Flow
- -150.47M
- Free Cash Flow
- -150.86M
- Free Cash Flow per Share
- -1.22
Dividends & Yields
NewAmsterdam Pharma Company pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.25%
- Earnings Yield
- -8.20%
Stock Price Statistics
- Beta
- 1.17
- 52-Week Price Change
- -44.70%
- 50-Day Moving Average
- 21.53
- 200-Day Moving Average
- 29.15
- Relative Strength Index (RSI)
- 47.28
- Average Volume (3m)
- 1.59M
Important Dates
NewAmsterdam Pharma Company upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
NewAmsterdam Pharma Company as a current ratio of 7.88, with Debt / Equity ratio of 0.03%
- Current Ratio
- 7.88
- Quick Ratio
- 7.88
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.02
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, NewAmsterdam Pharma Company has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NewAmsterdam Pharma Company EV to EBITDA ratio is -9.75, with an EV/FCF ratio of -13.21.
- EV to Sales
- 76.81
- EV to EBITDA
- -9.75
- EV to Free Cash Flow
- -13.21
- EV to Operating Cash Flow
- -13.24
Balance Sheet
NewAmsterdam Pharma Company has $628.24M in cash and marketable securities with $76.00K in debt, giving a net cash position of $628.17M billion.
- Cash & Marketable Securities
- $628.24M
- Total Debt
- $76.00K
- Net Cash
- $628.17M
- Net Cash Per Share
- $5.24
- Tangible Book Value Per Share
- $5.08
Margins
Gross margin is 97.84%, with operating margin of -900.07%, and net profit margin of -789.94%.
- Gross Margin
- 97.84%
- Operating Margin
- -900.07%
- Pretax Margin
- -785.29%
- Net Profit Margin
- -789.94%
- EBITDA Margin
- -787.56%
- EBIT Margin
- -788.51%
Analyst Forecast
The average price target for NewAmsterdam Pharma Company is $54.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $54.70
- Price Target Upside
- 171.60% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 11
- Revenue Growth Forecast
- -26.41%
- EPS Growth Forecast
- 16.12%
Scores
- Smart Score
- 7
- AI Score
- 52

